CEVEC closes a round table to meet a strong demand for viral vector technologies for cell and gene therapy


DGAP-News: CEVEC Pharmaceuticals GmbH / Keyword (s): Funding
27.07.2021 / 14:00
The issuer is solely responsible for the content of this advertisement.

CEVEC closes the growth financing round to meet strong demand in viral vector technologies for cell and gene therapy

Cologne, Germany, July 27e, 2021

CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cellular technology for the scalable manufacture of advanced biotherapeutics, today announced the successful completion of a round of organic growth funding. Being profitable in 2020, the company plans to use the funds to accelerate its growth and strengthen its cell line development capabilities to meet the growing market for viral vector production. CEVEC also announced that ELEVECTA (R) technology is currently being implemented in HEK293 as a second type of host cell. Since HEK293 is the most widely used host cell line in the manufacture of gene therapy, CEVEC expects a significant increase in demand from its customers and partners.

“CEVEC is at a very important stage of development. As pharmaceutical companies increasingly develop their gene therapy portfolios, now is the right time to invest and expand the company’s cell line development capabilities to meet the growing market for our technologies ”mentioned Dr Nicole Faust, Director General of CEVEC. “We are delighted to see the strong support from our investors in this capacity expansion program. We want to take the opportunity to thank them for their commitment, realizing that we share the same vision: to make CEVEC technologies the benchmark in the manufacture of viral vectors. ”

“Gene therapies are often the only treatment option for many serious and life-threatening diseases, and they have become a major driver of growth in the pharmaceutical and biotechnology fields. Therefore, the potential of new production technologies offered by CEVEC is enormous ”, mentioned Aristotelis Nastos, Head of Life Sciences and Clean Technologies at NRW.Bank. “We are delighted to be part of this round table with the goal of accelerating the growth of the company and becoming the market leader in stable vector manufacturing technologies in cell and gene therapy.

CEVEC provides superior solutions for vector manufacturing

The use of viral vectors in cell and gene therapy is vital. The challenge for the pharmaceutical industry is now to establish production processes capable of meeting the growing demand for volume and constant quality. With its highly scalable production cell lines for adeno-associated virus (AAV) and adenovirus-based vectors, CEVEC covers two of the most widely used viral vectors for delivering therapeutic genes to target cells and tissues. Proprietary technologies are characterized by unique advantages in the industry: CEVEC’s ELEVECTA (R) technology for stable AAV production is a revolutionary approach to AAV manufacturing, because the producing cells have all the necessary components integrated. stably in the genome, making the production processes of monoclonal antibodies. CAP (R) technology is best suited for the production of adenoviral vectors, as it is specifically designed to avoid the production of replication competent adenoviruses (RCA).

About CEVEC:

CEVEC is a leading provider of high performance cellular technologies for the manufacture of advanced biotherapeutics, from R&D to manufacturing. The company’s product portfolio includes platform technologies for gene therapy viral vectors, vaccines and complex recombinant proteins. With the ELEVECTA® TechnologyCEVEC offers a unique solution for the large-scale production of AAV vectors using producer cell lines free of helper viruses with all the necessary components stably integrated into the cell. The technology is based on cells in suspension and does not require expensive transfection reagents or cGMP plasmids. CEVEC CAP® technology based on human suspension cells is the ideal production platform for adenoviral vectors without RCA, lentiviral vectors, viral vaccines and exosomes. With the CAP-Go® Technology CEVEC provides a solution to the growing need for the recombinant production of complex and highly glycosylated protein molecules, in particular laminins, coagulation factors and plasma proteins.

About Gene Therapy Market:

The global gene therapy market size was estimated to be approximately USD 2.3 billion in 2020 and is expected to grow at a CAGR of 20.4% from 2021 to 2028.[1] With twenty cell and gene therapy products already approved and over four hundred human gene therapy clinical trials conducted worldwide, there is enormous potential for the treatment of rare inherited diseases and other devastating diseases. In addition, gene therapies are being developed for diseases like Alzheimer’s disease or Parkinson’s disease with a large number of patients, which should lead to a high demand for viral vector manufacturing capacity.

For more information, please visit the company website.

Follow CEVEC on LinkedIn and Twitter.


[1] Grand View Research (GVR), Gene Therapy Market Size, Share and Trend Analysis (02/2021), Report ID: GVR-2-68038-179-5

07.27.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this advertisement.

DGAP’s distribution services include regulatory announcements, financial / corporate news, and press releases.
Archives on www.dgap.de

Source link

Leave A Reply

Your email address will not be published.